Top

Published in:

01-06-2010 | Review Article

Prothrombin Complex Concentrates for Oral Anticoagulant Therapy-Related Intracranial Hemorrhage: A Review of the Literature

Authors: Eric M. Bershad, Jose I. Suarez

Published in: Neurocritical Care | Issue 3/2010

Abstract

Warfarin-related intracranial hemorrhage carries a high mortality and poor neurological outcome. Rapid reversal of coagulopathy is a cornerstone of medical therapy to halt bleeding progression; however the optimal approach remains undefined. Prothrombin complex concentrates have promising features that may rapidly reverse coagulopathy, but remain relatively unstudied. We aim to review the literature regarding the use of prothrombin complex concentrates in patients with warfarin-related intracranial hemorrhage. A comprehensive review of the literature was conducted using PUBMED and Google Scholar databases to identify the use of PCC in patients with warfarin-related intracranial hemorrhage. The characteristics abstracted included the type of PCC, dosing, study design, type of intracranial hemorrhage, changes in the INR, and adverse effects. Prothrombin complex concentrates are heterogenous in regards to factor concentration. PCC consistently reversed the INR in patients with intracranial hemorrhage. There is some evidence that PCC may reverse the INR more rapidly compared to fresh frozen plasma. Serious adverse effects were uncommon and included mainly thromboembolism. PCC has features which make it a promising therapy for patients with warfarin-related intracranial hemorrhage, and deserves more rigorous study in prospective-randomized controlled trials.

Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51.CrossRefPubMed

Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26(8):1471–7.PubMed

Butler AC, Tait RC. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev. 1998;12(1):35–44.CrossRefPubMed

Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897–902.PubMed

Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349(18):1703–12.CrossRefPubMed

Lavoie A, Ratte S, Clas D, Demers J, Moore L, Martin M, et al. Preinjury warfarin use among elderly patients with closed head injuries in a trauma center. J Trauma. 2004;56(4):802–7.CrossRefPubMed

Mina AA, Bair HA, Howells GA, Bendick PJ. Complications of preinjury warfarin use in the trauma patient. J Trauma. 2003;54(5):842–7.CrossRefPubMed

Neau JP, Couderq C, Ingrand P, Blanchon P, Gil R. Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis. 2001;11(3):195–200.CrossRefPubMed

Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990;21(5):726–30.PubMed

10.

Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22(5):571–6.PubMed

11.

Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006;37(1):256–62.CrossRefPubMed

12.

Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059–64.PubMed

13.

Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164(8):880–4.CrossRefPubMed

14.

Bershad EM, Farhadi S, Suri MF, Feen ES, Hernandez OH, Selman WR, et al. Coagulopathy and inhospital deaths in patients with acute subdural hematoma. J Neurosurg. 2008;109(4):664–9.CrossRefPubMed

15.

Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77(3):477–80.PubMed

16.

Baglin T. Management of warfarin (coumarin) overdose. Blood Rev. 1998;12(2):91–8.CrossRefPubMed

17.

Taberner DA, Thomson JM, Poller L. Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. Br Med J. 1976;2(6027):83–5.CrossRefPubMed

18.

Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83(2):137–43.CrossRefPubMed

19.

Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edition. Chest. 2008;133(6 Suppl):160S–98S.CrossRefPubMed

20.

Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999, 83(2):286–288 (A286–287).

21.

Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20):2469–73.CrossRefPubMed

22.

Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol. 2005;42(3):365–70.CrossRefPubMed

23.

Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): 3rd edition—2005 update. Br J Haematol. 2006;132(3):277–85.CrossRefPubMed

24.

Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127–37.CrossRefPubMed

25.

Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352(8):777–85.CrossRefPubMed

26.

rFVIIa in ICH in patients treated with anticoagulants or anti-platelets. www.clinicaltrials.gov.

27.

Appelboam R, Thomas EO. The headache over warfarin in British neurosurgical intensive care units: a national survey of current practice. Intensive Care Med. 2007;33(11):1946–53.CrossRefPubMed

28.

Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181(9):492–7.PubMed

29.

Tullis JL, Melin M. Management of Christmas disease and Stuart-Prower deficiency with a prothrombin-complex concentrate (factors II, VII, IX, X). Bibl Haematol. 1968;29:1134–9.PubMed

30.

Sandler SG, Rath CE, Ruder A. Prothrombin complex concentrates in acquired hypoprothrombinemia. Ann Intern Med. 1973;79(4):485–91.PubMed

31.

Josic D, Hoffer L, Buchacher A, Schwinn H, Frenzel W, Biesert L, et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res. 2000;100(5):433–41.CrossRefPubMed

32.

Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res. 1999;95(4 Suppl 1):S7–12.CrossRefPubMed

33.

McQuillan AM, Eikelboom JW, Hankey GJ, Baker R, Thom J, Staton J, et al. Protein Z in ischemic stroke and its etiologic subtypes. Stroke. 2003;34(10):2415–9.CrossRefPubMed

34.

Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004;113(6):371–8.CrossRefPubMed

35.

Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115(4):998–1001.CrossRefPubMed

36.

Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98(4):790–7.PubMed

37.

Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 1999;45(5):1113–8. discussion 1118–1119.CrossRefPubMed

38.

Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg. 2000;14(5):458–61.CrossRefPubMed

39.

Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992;23(7):972–7.PubMed

40.

Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4(5):967–70.CrossRefPubMed

41.

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6(4):622–31.CrossRefPubMed

42.

Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116(3):619–24.CrossRefPubMed

43.

Vigue B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med. 2007;33(4):721–5.CrossRefPubMed

44.

Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol. 2003;82(2):121–3.PubMed

45.

van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118(3):313–20.CrossRefPubMed

46.

Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12(4):R105.CrossRefPubMed

47.

Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;115(6):455–9.CrossRefPubMed

48.

Hellstern P, Halbmayer WM, Kohler M, Seitz R, Muller-Berghaus G. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999;95(4 Suppl 1):S3–6.CrossRefPubMed

49.

Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev. 2007;21(1):37–48.CrossRefPubMed

50.

Pindur G, Morsdorf S. The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. Thromb Res. 1999;95(4 Suppl 1):S57–61.CrossRefPubMed

51.

Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol. 2001;114(2):271–80.CrossRefPubMed

52.

Crawford JH, Augustson BM. Prothrombinex use for the reversal of warfarin: is fresh frozen plasma needed? Med J Aust. 2006;184(7):365–6.PubMed

53.

Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171–7.CrossRefPubMed

54.

Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR. Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med. 1974;81(6):766–70.PubMed

55.

Schimpf K, Zeltsch C, Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A. Lancet. 1982;2(8306):1043.CrossRefPubMed

56.

Hampton KK, Preston FE, Lowe GD, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol. 1993;84(2):279–84.CrossRefPubMed

57.

Aledort LM. Factor IX and thrombosis. Scand J Haematol Suppl. 1977;30:40–2.PubMed

58.

Kohler M, Heiden M, Harbauer G, Miyashita C, Morsdorf S, Braun B, et al. Comparison of different prothrombin complex concentrates–in vitro and in vivo studies. Thromb Res. 1990;60(1):63–70.CrossRefPubMed

59.

Hellstern P, Beeck H, Fellhauer A, Fischer A, Faller-Stockl B. Factor VII and activated-factor-VII content of prothrombin complex concentrates. The PCC Study Group. Vox Sang. 1997;73(3):155–61.CrossRefPubMed

60.

Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95(4 Suppl 1):S13–7.CrossRefPubMed

61.

White GC II, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood. 1977;49(2):159–70.PubMed

62.

Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G, et al. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost. 1995;73(4):675–9.PubMed

63.

Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits. Blood. 1982;59(2):401–7.PubMed

64.

Lusher JM. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Hematol. 1993;30(2 Suppl 1):36–40.PubMed

65.

Roddie PH, Stirling C, Mayne EE, Ludlam CA. Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX. Thromb Haemost. 1999;81(4):667.PubMed

66.

Pindur G, Morsdorf S, Schenk JF, Krischek B, Heinrich W, Wenzel E. The overdosed patient and bleedings with oral anticoagulation. Semin Thromb Hemost. 1999;25(1):85–8.CrossRefPubMed

67.

Preiss DU, Eberspacher B, Abdullah D, Rosner I. Safety of vapour heated prothrombin complex concentrate (PCC) Prothromplex S-TIM 4. Thromb Res. 1991;63(6):651–9.CrossRefPubMed

68.

Morfini M, Longo G, Berntorp E, Cinotti S, Filimberti E, Messori A, et al. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate. Thromb Res. 1993;71(3):175–84.CrossRefPubMed

69.

Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79(3):826–31.PubMed

70.

Seitz R, Dodt J. Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb Res. 1999;95(4 Suppl 1):S19–23.CrossRefPubMed

71.

Taketomi T, Szlam F, Levy JH, Tanaka KA. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2008;19(1):106–8.CrossRefPubMed

72.

Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res. 2007;119(5):643–51.CrossRefPubMed

73.

Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37(6):1465–70.CrossRefPubMed

74.

Kalina M, Tinkoff G, Gbadebo A, Veneri P, Fulda G. A protocol for the rapid normalization of INR in trauma patients with intracranial hemorrhage on prescribed warfarin therapy. Am Surg. 2008;74(9):858–61.PubMed

75.

Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol. 1998;20(6):363–7.CrossRefPubMed

Title: Prothrombin Complex Concentrates for Oral Anticoagulant Therapy-Related Intracranial Hemorrhage: A Review of the Literature
Authors: Eric M. Bershad
Jose I. Suarez
Publication date: 01-06-2010
Publisher: Humana Press Inc
Published in: Neurocritical Care / Issue 3/2010
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI: https://doi.org/10.1007/s12028-009-9310-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prothrombin Complex Concentrates for Oral Anticoagulant Therapy-Related Intracranial Hemorrhage: A Review of the Literature

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Continuous Selective Intraarterial Infusion of Nimodipine for Therapy of Refractory Cerebral Vasospasm

Increased Cortisol Levels are Associated with Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage

Severe Alcohol Hand Rub Overdose Inducing Coma, Watch After H1N1 Pandemic

Ondine’s Curse with Accompanying Trigeminal and Glossopharyngeal Neuralgia Secondary to Medullary Telangiectasia

Metabolic Crisis After Traumatic Brain Injury is Associated with a Novel Microdialysis Proteome

Coma from Worsening Spontaneous Intracranial Hypotension After Subdural Hematoma Evacuation